What question did this study set out to answer?

The aim is to clarify the role of eicosapentaenoic acid in suppressing angiogenesis associated with colon cancer fibroblasts.

May 2, 2019Oncology ReportsOpen Access

Eicosapentaenoic acid suppresses angiogenesis via reducing secretion of IL‑6 and VEGF from colon cancer‑associated fibroblasts

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial investigates eicosapentaenoic acid's impact on angiogenesis in colon cancer fibroblasts, suggesting its potential therapeutic role.

The aim is to clarify the role of eicosapentaenoic acid in suppressing angiogenesis associated with colon cancer fibroblasts.
Evaluated IL-6 and VEGF secretion using ELISA from CAFs and normal fibroblasts with or without EPA treatment.
Assessed ERK phosphorylation via western blotting after CAF treatment with 30 µM EPA.
Conducted in vitro angiogenesis assay using HUVECs cultured with CAF supernatants treated with EPA.
EPA significantly reduced IL-6 and VEGF secretion from CAFs compared to untreated controls (exact p-values not provided).
30 µM EPA inhibited ERK phosphorylation in CAFs, demonstrating a clear signaling pathway impact.
The angiogenesis assay showed suppressed tubular formation in HUVECs exposed to CAF supernatants treated with EPA.

Ando et al. (2019) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial investigates eicosapentaenoic acid's impact on angiogenesis in colon cancer fibroblasts, suggesting its potential therapeutic role.